Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 8 months 11 days ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 8 months 11 days ago

Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025
Biophytis révèle ses résultats 2024 et perspectives 2025 avec lancement d'études cliniques et renforcement de sa plateforme technologique de découverte de médicaments. Communiqué de presse publié par Biophytis SA

Biophytis Résultats 2024 Études Cliniques Découverte De Médicaments Perspectives 2025
BRIEF

published on 07/08/2025 at 07:05, 8 months 14 days ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
BRIEF

published on 07/08/2025 at 07:05, 8 months 14 days ago

Biophytis présente à la Conférence mondiale sur le vieillissement et le rajeunissement 2025

Innovation Biophytis Longévité Sarcopénie ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 8 months 14 days ago

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Biophytis SA announces participation in ARC 2025 to present results of BIO101 in sarcopenia at the World Aging & Rejuvenation Conference, aiming to strengthen scientific visibility and expand in the longevity market

Sarcopenia Biophytis SA BIO101 Longevity Market ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 8 months 14 days ago

Biophytis au cœur de l’innovation dans la longévité à la conference World Aging & Rejuvenation 2025
Biophytis participe à la 7e conférence mondiale sur le vieillissement et le rajeunissement pour présenter ses résultats sur la sarcopénie et le candidat-médicament BIO101

Biophytis Conference Longévité BIO101 SARA Program
PRESS RELEASE

published on 07/08/2025 at 06:59, 8 months 14 days ago

Biophytis au cœur de l’innovation dans la longévité à la conference World Aging & Rejuvenation 2025
Biophytis annonce sa participation à la conférence World Aging & Rejuvenation 2025 à Vienne. Présentation des résultats du programme SARA sur la sarcopénie avec BIO101

Biophytis Longévité Sarcopénie World Aging & Rejuvenation 2025 SARA
BRIEF

published on 07/07/2025 at 07:05, 8 months 15 days ago

Biophytis : Avancée sur le Marché de l'Obésité

Biophytis Marché Obésité GLP-1 Masse Musculaire
BRIEF

published on 07/07/2025 at 07:05, 8 months 15 days ago

Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis BIO101 Muscle Preservation GLP-1 Therapies Obesity Market
REGULATED PRESS RELEASE

published on 07/07/2025 at 07:00, 8 months 15 days ago

Obesity: Biophytis Charts Its Course Toward a Booming Market
Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market

BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA

Published on 03/20/2026 at 23:00, 2 days 1 hour ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 2 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 3 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 10 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 11 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 5 hours 56 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 11 hours 55 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 1 hour ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days 5 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 5 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 6 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 6 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 2 days 6 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News